Merck & Company Inc (MRK)vsVeracyte Inc (VCYT)
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
VCYT
Veracyte Inc
$40.87
-2.76%
HEALTHCARE · Cap: $3.41B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 11747% more annual revenue ($66.57B vs $561.90M). VCYT leads profitability with a 20.4% profit margin vs 4.8%. VCYT trades at a lower P/E of 30.3x. VCYT earns a higher WallStSmart Score of 60/100 (C+).
MRK
Hold36
out of 100
Grade: F
VCYT
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Margin of Safety
+58.8%
Fair Value
$87.26
Current Price
$40.87
$46.39 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Earnings expanding 288.9% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 20 of every $100 in revenue as profit
Reasonable price relative to book value
15.5% revenue growth
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Premium valuation, high expectations priced in
ROE of 6.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : VCYT
The strongest argument for VCYT centers on EPS Growth, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 20.4% and operating margin at 15.3%. Revenue growth of 15.5% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : VCYT
The primary concerns for VCYT are P/E Ratio, Return on Equity.
Key Dynamics to Monitor
MRK profiles as a value stock while VCYT is a growth play — different risk/reward profiles.
VCYT carries more volatility with a beta of 1.93 — expect wider price swings.
VCYT is growing revenue faster at 15.5% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
VCYT scores higher overall (60/100 vs 36/100), backed by strong 20.4% margins and 15.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Veracyte Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Veracyte, Inc. is a genomic diagnostics company in the United States and internationally. The company is headquartered in South San Francisco, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?